• 1
    Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 20952106.
  • 2
    Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011;154:445456. Epub 2011 Feb 14
  • 3
    Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646655.
  • 4
    Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 13891397.
  • 5
    Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796806. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786
  • 6
    Riva C, Lai A, Caramma I. Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum Retroviruses 2010; 26: 4149.
  • 7
    Alteri C, Svicher V, Gori C et al. Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs. BMC Infect Dis 2009; 9: 111.
  • 8
    Bracciale L, Colafigli M, Zazzi M et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. JAC 2009; 64: 607615.
  • 9
    Bennet DE, Camacho R, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.
  • 10
    Torti C, Lapadula G, Izzo I et al. Heterogeneity and penetration of HIV-1 non-subtypes B virus in an Italian province: public health implications. Epidemiol Infect 2010; 138: 12981307.
  • 11
    Harrison L, Castro H, Cane P et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 2010; 24: 19171922.